#ariba_ref_name	ref_name	gene	var_only	flag	reads	cluster	ref_len	ref_base_assembled	pc_ident	ctg	ctg_len	ctg_cov	known_var	var_type	var_seq_type	known_var_change	has_known_var	ref_ctg_change	ref_ctg_effect	ref_start	ref_end	ref_nt	ctg_start	ctg_end	ctg_nt	smtls_total_depth	smtls_nts	smtls_nts_depth	var_description	free_text
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	531	4932	16S	1529	1529	99.93	16S.l6.c4.ctg.1	2604	560.0	0	.	n	.	0	C326T	SNP	326	326	C	848	848	T	663	T,C,A	574,2,1	.	.
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	531	4932	16S	1529	1529	99.93	16S.l6.c4.ctg.1	2604	560.0	1	SNP	n	C1184T	0	.	.	1184	1184	C	1706	1706	C	697	C,A	603,1	16S.rDNA_WHO_F_01361c:0:1:C1184T:16S.1184T:E coli C1192T. Resistance to Spectinomycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	7704	23S	2890	2890	99.93	23S.l15.c4.ctg.1	3998	576.8	0	.	n	.	0	T695C	SNP	695	695	T	1268	1268	C	576	C,T,A	476,2,1	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	7704	23S	2890	2890	99.93	23S.l15.c4.ctg.1	3998	576.8	0	.	n	.	0	T1971C	SNP	1971	1971	T	2544	2544	C	750	C,A	652,1	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	7704	23S	2890	2890	99.93	23S.l15.c4.ctg.1	3998	576.8	1	SNP	n	A2045G	0	.	.	2045	2045	A	2618	2618	A	763	A,G,C	655,1,1	23S.rDNA_WHO_F_01358c:0:1:A2045G:23S.2045G:E coli A2059G. High-level resistance to Azithromycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	7704	23S	2890	2890	99.93	23S.l15.c4.ctg.1	3998	576.8	1	SNP	n	C2597T	0	.	.	2597	2597	C	3170	3170	C	689	C	567	23S.rDNA_WHO_F_01358c:0:1:C2597T:23S.2597T :E coli C2611T. Low-level resistance to Azithromycin	.
folP.WHO_O_01412c	folP.WHO_O_01412c	1	1	27	738	folP	855	855	100.0	folP.l15.c4.ctg.1	2024	108.7	1	SNP	p	R229S	1	.	.	685	687	AGC	1240	1242	AGC	174;175;175	A;G;C	150;152;150	folP.WHO_O_01412c:1:1:R229S:folP.228S:Resistance to sulphonamides	.
gyrA.WHO_M_01098	gyrA.WHO_M_01098	1	1	539	1766	gyrA	2751	2751	99.96	gyrA.l6.c4.ctg.1	3889	136.0	0	.	p	.	0	G95A	NONSYN	283	285	GGC	841	843	GCC	122;122;121	G;C;C	105;106;106	.	.
gyrA.WHO_M_01098	gyrA.WHO_M_01098	1	1	539	1766	gyrA	2751	2751	99.96	gyrA.l6.c4.ctg.1	3889	136.0	1	SNP	p	S91F	1	.	.	271	273	TTC	829	831	TTC	125;124;124	T;T;C	104;107;111	gyrA.WHO_M_01098:1:1:S91F:gyrA.91F:Resistance to fluoroquinolones	.
mtrR.WHO_L_00489c	mtrR.WHO_L_00489c	1	1	27	678	mtrR	633	633	100.0	mtrR.l15.c4.ctg.1	1738	116.8	1	SNP	p	G45D	1	.	.	133	135	GAC	704	706	GAC	182;180;179	G,A;A,G;C	156,1;151,1;160	mtrR.WHO_L_00489c:1:1:G45D:mtrR.45D:Increased efflux of antimicrobials, e.g. macrolides and b-lactam antimicrobials, that are substrates of the MtrCDE efflux pump	.
mtrR_promoter.WHO_F	mtrR_promoter.WHO_F	0	0	531	436	mtrR_promoter	250	250	99.6	mtrR_promoter.l15.c4.ctg.1	1452	90.0	0	.	n	.	0	A197.	DEL	197	197	A	816	816	A	155	A	143	.	.
parC.WHO_G_00206c	parC.WHO_G_00206c	1	1	539	1602	parC	2304	2304	99.91	parC.l6.c4.ctg.1	3488	137.5	0	.	p	.	0	S87N	NONSYN	259	261	AGT	815	817	AAT	155;155;155	A;A,G;T	125;131,1;125	.	.
parC.WHO_G_00206c	parC.WHO_G_00206c	1	1	539	1602	parC	2304	2304	99.91	parC.l6.c4.ctg.1	3488	137.5	0	.	p	.	0	I596V	NONSYN	1786	1788	ATT	2342	2344	GTT	187;186;186	G;T;T	167;161;158	.	.
parC.WHO_G_00206c	parC.WHO_G_00206c	1	1	539	1602	parC	2304	2304	99.91	parC.l6.c4.ctg.1	3488	137.5	1	SNP	p	D86N	0	.	.	256	258	GAC	812	814	GAC	156;156;156	G;A,C;C	138;133,1;139	parC.WHO_G_00206c:1:1:D86N:parC.86N:Resistance to fluoroquinolones	.
parC.WHO_G_00206c	parC.WHO_G_00206c	1	1	539	1602	parC	2304	2304	99.91	parC.l6.c4.ctg.1	3488	137.5	1	SNP	p	S88P	0	.	.	262	264	TCC	818	820	TCC	155;155;154	T,G;C;C	126,1;132;136	parC.WHO_G_00206c:1:1:S88P:parC.88P:Resistance to fluoroquinolones	.
parE.WHO_F_01528c	parE.WHO_F_01528c	1	1	539	1322	parE	1986	1986	99.85	parE.l6.c4.ctg.1	3225	122.6	0	.	p	.	0	R340C	NONSYN	1018	1020	CGC	1613	1615	TGC	173;174;173	T;G;C	144;148;148	.	.
parE.WHO_F_01528c	parE.WHO_F_01528c	1	1	539	1322	parE	1986	1986	99.85	parE.l6.c4.ctg.1	3225	122.6	0	.	p	.	0	D437N	NONSYN	1309	1311	GAT	1904	1906	AAT	172;171;171	A;A;T,C	151;151;143,1	.	.
parE.WHO_F_01528c	parE.WHO_F_01528c	1	1	539	1322	parE	1986	1986	99.85	parE.l6.c4.ctg.1	3225	122.6	1	SNP	p	G410V	0	.	.	1228	1230	GGC	1823	1825	GGC	167;165;165	G;G,A;C	146;141,1;140	parE.WHO_F_01528c:1:1:G410V:parE.410V:Resistance to fluoroquinolones	.
penA.21.001	penA.21.001	1	1	27	1260	penA	1752	1752	100.0	penA.l15.c4.ctg.1	2980	126.4	1	SNP	p	A311V	0	.	.	931	933	GCA	1523	1525	GCA	159;158;157	G;C;A	139;137;138	penA.21.001:1:1:A311V:penA.311V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.21.001	penA.21.001	1	1	27	1260	penA	1752	1752	100.0	penA.l15.c4.ctg.1	2980	126.4	1	SNP	p	I312M	0	.	.	934	936	ATC	1526	1528	ATC	157;156;157	A;T,A;C	145;136,1;143	penA.21.001:1:1:I312M:penA.312M:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.21.001	penA.21.001	1	1	27	1260	penA	1752	1752	100.0	penA.l15.c4.ctg.1	2980	126.4	1	SNP	p	V316T	0	.	.	946	948	GTG	1538	1540	GTG	163;164;165	G,A;T;G	144,1;144;144	penA.21.001:1:1:V316T:penA.316T:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.21.001	penA.21.001	1	1	27	1260	penA	1752	1752	100.0	penA.l15.c4.ctg.1	2980	126.4	1	SNP	p	V316P	0	.	.	946	948	GTG	1538	1540	GTG	163;164;165	G,A;T;G	144,1;144;144	penA.21.001:1:1:V316P:penA.316P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.21.001	penA.21.001	1	1	27	1260	penA	1752	1752	100.0	penA.l15.c4.ctg.1	2980	126.4	1	SNP	p	T484S	0	.	.	1450	1452	ACC	2042	2044	ACC	160;160;160	A;C;C	138;135;141	penA.21.001:1:1:T484S:penA.483S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.21.001	penA.21.001	1	1	27	1260	penA	1752	1752	100.0	penA.l15.c4.ctg.1	2980	126.4	1	SNP	p	A502V	1	.	.	1504	1506	GTG	2096	2098	GTG	170;169;169	G;T;G	140;129;134	penA.21.001:1:1:A502V:penA.501V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.21.001	penA.21.001	1	1	27	1260	penA	1752	1752	100.0	penA.l15.c4.ctg.1	2980	126.4	1	SNP	p	V502P	0	.	.	1504	1506	GTG	2096	2098	GTG	170;169;169	G;T;G	140;129;134	penA.21.001:1:1:V502P:penA.501P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.21.001	penA.21.001	1	1	27	1260	penA	1752	1752	100.0	penA.l15.c4.ctg.1	2980	126.4	1	SNP	p	G543S	0	.	.	1627	1629	GGT	2219	2221	GGT	162;163;161	G;G;T	133;139;135	penA.21.001:1:1:G543S:penA.542S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.21.001	penA.21.001	1	1	27	1260	penA	1752	1752	100.0	penA.l15.c4.ctg.1	2980	126.4	1	SNP	p	G546S	0	.	.	1636	1638	GGC	2228	2230	GGC	161;161;161	G;G;C	136;140;132	penA.21.001:1:1:G546S:penA.545S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.21.001	penA.21.001	1	1	27	1260	penA	1752	1752	100.0	penA.l15.c4.ctg.1	2980	126.4	1	SNP	p	P552S	0	.	.	1654	1656	CCG	2246	2248	CCG	155;155;155	C;C,T;G	121;133,1;128	penA.21.001:1:1:P552S:penA.551S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
ponA.WHO_G_00106	ponA.WHO_G_00106	1	1	27	1636	ponA	2397	2397	100.0	ponA.l15.c4.ctg.1	3483	140.5	1	SNP	p	L421P	1	.	.	1261	1263	CCG	1819	1821	CCG	154;153;149	C,A;C;G,A	126,1;127;119,1	ponA.WHO_G_00106:1:1:L421P:ponA.421P:High-level chromosomally-mediated penicillin resistance	.
porA.NCCP11945	porA.NCCP11945	1	0	531	786	porA	1146	1146	99.83	porA.l6.c4.ctg.1	2317	101.7	0	.	p	.	0	M83fs	FSHIFT	247	247	A	818	818	C	127	C	109	.	.
porB1b.WHO_P_02204c	porB1b.WHO_P_02204c	1	1	539	984	porB1b	1047	1047	98.76	porB1b.l6.c4.ctg.1	2220	131.9	1	SNP	p	G120K	1	G120K	NONSYN	358	360	GGC	953	955	AAG	223;223;224	A;A;G	195;188;192	porB1b.WHO_P_02204c:1:1:G120K:porB1b.120K:G101K. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_P_02204c	porB1b.WHO_P_02204c	1	1	539	984	porB1b	1047	1047	98.76	porB1b.l6.c4.ctg.1	2220	131.9	0	.	p	.	0	E212D	NONSYN	634	636	GAA	1229	1231	GAT	227;227;227	G;A;T	196;192;188	.	.
porB1b.WHO_P_02204c	porB1b.WHO_P_02204c	1	1	539	984	porB1b	1047	1047	98.76	porB1b.l6.c4.ctg.1	2220	131.9	0	.	p	.	0	H213G	NONSYN	637	639	CAT	1232	1234	GGT	228;227;225	G;G,T;T,A	198;195,1;194,1	.	.
porB1b.WHO_P_02204c	porB1b.WHO_P_02204c	1	1	539	984	porB1b	1047	1047	98.76	porB1b.l6.c4.ctg.1	2220	131.9	0	.	p	.	0	V215A	NONSYN	643	645	GTT	1238	1240	GCT	224;224;224	G;C;T,C	194;194;187,2	.	.
porB1b.WHO_P_02204c	porB1b.WHO_P_02204c	1	1	539	984	porB1b	1047	1047	98.76	porB1b.l6.c4.ctg.1	2220	131.9	0	.	p	.	0	I218M	NONSYN	652	654	ATC	1247	1249	ATG	222;222;222	A;T;G	194;193;191	.	.
porB1b.WHO_P_02204c	porB1b.WHO_P_02204c	1	1	539	984	porB1b	1047	1047	98.76	porB1b.l6.c4.ctg.1	2220	131.9	0	.	p	.	0	R257T	NONSYN	769	771	AGG	1364	1366	ACG	177;177;176	A,C;C,A;G	155,1;156,1;152	.	.
porB1b.WHO_P_02204c	porB1b.WHO_P_02204c	1	1	539	984	porB1b	1047	1047	98.76	porB1b.l6.c4.ctg.1	2220	131.9	0	.	p	.	0	A259V	NONSYN	775	777	GCT	1370	1372	GTT	177;176;176	G,T;T,A;T	148,2;149,1;150	.	.
porB1b.WHO_P_02204c	porB1b.WHO_P_02204c	1	1	539	984	porB1b	1047	1047	98.76	porB1b.l6.c4.ctg.1	2220	131.9	0	.	p	.	0	D297N	NONSYN	889	891	GAC	1484	1486	AAC	167;167;168	A;A;C,A	149;148;143,1	.	.
porB1b.WHO_P_02204c	porB1b.WHO_P_02204c	1	1	539	984	porB1b	1047	1047	98.76	porB1b.l6.c4.ctg.1	2220	131.9	1	SNP	p	D121N	0	.	.	361	363	GAC	956	958	GAC	224;224;224	G,A;A,G;C	189,1;193,1;190	porB1b.WHO_P_02204c:1:1:D121N:porB1b.121N:A102N. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_P_02204c	porB1b.WHO_P_02204c	1	1	539	984	porB1b	1047	1047	98.76	porB1b.l6.c4.ctg.1	2220	131.9	1	SNP	p	A121D	1	.	.	361	363	GAC	956	958	GAC	224;224;224	G,A;A,G;C	189,1;193,1;190	porB1b.WHO_P_02204c:1:1:A121D:porB1b.121D:A102D. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
rpoB.WHO_M_02157	rpoB.WHO_M_02157	1	1	27	3208	rpoB	4179	4179	100.0	rpoB.l15.c4.ctg.1	5250	183.0	1	SNP	p	H553N	1	.	.	1657	1659	AAT	2152	2154	AAT	179;179;177	A,C;A;T	160,1;155;160	rpoB.WHO_M_02157:1:1:H553N:rpoB.553N:H552N. High-level resistance to Rifampicin	.
rpsJ.WHO_Y_02241	rpsJ.WHO_Y_02241	1	1	27	472	rpsJ	312	312	100.0	rpsJ.l6.c4.ctg.1	1592	88.8	1	SNP	p	V57M	1	.	.	169	171	ATG	804	806	ATG	164;163;162	A;T,G;G	147;144,1;141	rpsJ.WHO_Y_02241:1:1:V57M:rpsJ.57M:Chromosomally-mediated resistance to tetracyclines	.
